treatment

Nearly one year of treatment with frexalimab, an antibody being developed by Sanofi, significantly reduced the blood levels of neurofilament light chain (NfL), a biomarker of nerve cell damage that typically is elevated in people with multiple sclerosis (MS). That’s according to new data from a company-sponsored…

The U.S Food and Drug Administration (FDA) authorized an investigational new drug application from Synaptogenix, clearing the company to launch a clinical trial to test whether its lead candidate bryostatin-1 can prevent cognitive decline in people with multiple sclerosis (MS). The open-label, Phase 1 clinical trial (NCT06190912),…

Note: This column describes the author’s own experiences with sleep medications and antidepressants. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. Many years ago, it was brought to my attention that I suffer from insomnia and chronic fatigue.

When given a specific set of chemical cues, immune cells called neutrophils are able to take on healing abilities that allow them to help repair damaged nerve fibers, a study by U.S. researchers found. The researchers hope to build on this discovery to create new treatments for multiple sclerosis…

Researchers have identified characteristics of regulatory T-cells (Tregs) — a family of immune cells that help keep harmful immune reactions in check — that could make it easier to develop targeted treatments for autoimmune conditions like multiple sclerosis (MS). They found that Tregs exist as a common pool that…

Two inverse vaccines from Nykode Therapeutics — developed to teach the immune system not to respond against its own body — worked to reduce disease severity in a mouse model of multiple sclerosis (MS), new data show. This adds to earlier findings that the company’s experimental approach and…

June is a special month for me. Eight years ago I had an autologous hematopoietic stem cell transplant (aHSCT) in Moscow to treat my multiple sclerosis (MS). On June 22, I celebrated my eighth stem cell birthday! A stem cell transplant, or “stemmie day,” is when patients…

The European Commission has approved a subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab) to treat adults with multiple sclerosis (MS). The approval makes the new formulation available in the European Union for the same indications as the original intravenous (into-the-vein) formulation, which is available to people with relapsing…

The National Institute of Neurological Disorders and Stroke has awarded a $2.9 million, five-year grant to a research project that aims to advance a new technology that could improve stem cell therapies for multiple sclerosis (MS) and other neurological disorders. “The work we plan to undertake has significant implications…

Note: This column describes the author’s own experiences with high-dose steroids to treat multiple sclerosis (MS). Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. My first experience treating an MS relapse with intravenous steroids was interesting.

Switching to one of the anti-CD20 targeting therapies Ocrevus (ocrelizumab) or rituximab may be an effective strategy for discontinuing Tysabri (natalizumab) treatment in multiple sclerosis (MS) patients at risk for progressive multifocal leukoencephalopathy (PML), according to a systematic review. The study, “Switching from natalizumab to an…

Most patients with nonactive secondary progressive multiple sclerosis (SPMS) who took foralumab nasal spray for at least six months saw a decrease in microglial activity in their brains, according to its developer Tiziana Life Sciences. The results were gleaned from PET imaging data from 10 nonactive SPMS patients…

England’s National Institute for Health and Care Excellence (NICE) has updated its guidance on the use of Mavenclad (cladribine) in people with aggressive relapsing-remitting multiple sclerosis (RRMS) in ways that should help eligible patients be able to access the medication sooner. The new guidelines have less stringent…

A large proportion of people with multiple sclerosis (MS) experience headaches as a result of their condition, and treatment with interferon-based therapies seems to increase the risk of worsening headaches or developing new ones, a study found. In contrast, the CD20 antibody rituximab that’s used off-label in MS…

Resistance training by middle-aged people with multiple sclerosis (MS) was linked with significant improvements in muscle strength in a recent meta-analysis of previous clinical trial data. The analysis indicated the benefits of such training, which is designed to boost strength and endurance, were more variable in fatigue and quality…

Helius Medical Technologies said it has a booth at a meeting for multiple sclerosis (MS) professionals to showcase its PoNS device and the progress made over the last year in providing access to the neuromodulation device, which is designed to improve walking ability in people with MS.

Progentos Therapeutics said it received $65 million in funding to support the development of myelin regeneration medications able to restore function in people with multiple sclerosis (MS) and other diseases marked by myelin loss. The biotech company said it will use the funds to advance its MS program…

A Marquette University team is leading a new project that will combine balance and cardio training with the goal of improving the walking abilities of people with multiple sclerosis (MS). Led by Marquette biomedical engineering professor Brian Schmit, PhD, the project — which is supported by a $3.34 million…

People with multiple sclerosis (MS) who start treatment with a mild-to-moderate efficacy disease-modifying therapy (DMT) were more likely to switch to another DMT, an analysis of the German MS Registry finds. Starting a DMT between 2014 and 2017 was also a predictor of switching. Disease activity despite treatment…

Alternative splicing, a biological process that allows a single gene to code for multiple proteins, is extensively disrupted in immune cells isolated from untreated multiple sclerosis (MS) patients, and long-term treatment with interferon beta-based therapies largely corrects the defects, a study found. “Alternative splicing is a potential biomarker warning…

A small molecule called ESI1 stimulated the repair of the myelin sheath, the fatty coating on nerve fibers that is damaged in multiple sclerosis (MS), a study found. In an MS mouse model, this resulted in improved motor function and nerve cell communication, as well as reduced signs…

The National Multiple Sclerosis Society has awarded Inflectis BioScience a grant valued at $649,601 to advance the preclinical development of IFB-048, the company’s experimental treatment to promote myelin repair in multiple sclerosis (MS). “This grant along with the support from the Society are a testimony…

A committee of the European Medicines Agency (EMA) is recommending the approval of a subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab) for people with multiple sclerosis (MS) in the European Union. The Committee for Medicinal Products for Human Use, known as CHMP, specifically recommended that this new formulation…

NKTR-0165, an antibody that targets the tumor necrosis factor receptor type 2 (TNFR2), will continue to be developed by Nektar Therapeutics as a candidate for treating multiple sclerosis (MS) and other autoimmune diseases. The experimental therapy was developed under a 2021 collaboration between Nektar and Biolojic…

A lower dose of the experimental oral therapy vidofludimus calcium (IMU-838) was not as effective as higher doses at reducing lesions in people with relapsing-remitting multiple sclerosis (RRMS), extended data from the therapy’s Phase 2 EMPhASIS trial show. “We found that doses of 30 mg and 45 mg,…

People with multiple sclerosis (MS) who are being treated with Tysabri (natalizumab) tend to prefer receiving the medication as a subcutaneous (under-the-skin) injection rather than an intravenous (into-the-vein) infusion, according to new data from an observational study. “Based on current data, there is a trend toward patients’ preference…

Fully 70% of patients with nonactive secondary progressive multiple sclerosis (SPMS) who received foralumab nasal spray in an expanded access program (EAP) experienced a lessening in fatigue levels after six months of treatment. That’s according to early findings from the EAP — a program that enables patients with serious…

A subcutaneous (under-the-skin) formulation of Ocrevus (ocrelizumab) helped most adults with multiple sclerosis (MS) remain free of clinical relapses and new or worsening brain lesions, according to one-year data from the Phase 3 OCARINA II study. Given twice a year as a 10-minute injection, this formulation of Ocrevus…

Viatris has launched a generic version of low-dose Copaxone (glatiramer acetate) in the Canadian market for the treatment of people with relapsing-remitting multiple sclerosis (RRMS) who retain the ability to walk. Called Glatiramer Acetate Injection 20 mg/mL, the product was approved in Canada as a generic of…

Two years of treatment with Briumvi (ublituximab) in clinical trials resulted in a confirmed reduction in disability for more than 1 in 10 people with early relapsing multiple sclerosis (MS) who had not received any prior treatment. That’s according to new data from the ULTIMATE Phase 3 trials,…